Neo Ivy Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$713K	Buy	32,036 +26,028	+433%	+$622K	0.19%	179
2025 Q4	$160K	Sell	6,008 -56,560	-90%	-$1.35M	0.03%	284
2025 Q3	$1.34M	Buy	+62,568	New	+$1.48M	0.33%	115
2025 Q1	–	Sell	-57,504	Closed	-$1.05M	–	272
2024 Q4	$1.05M	Buy	57,504 +54,022	+1,551%	+$872K	0.21%	154
2024 Q3	$54K	Sell	3,482 -199,566	-98%	-$3.33M	0.02%	245
2024 Q2	$3.3M	Buy	+203,048	New	+$3.28M	0.65%	68
2023 Q4	$0	Buy	+3	New	+$72	﹤0.01%	276
2023 Q3	–	Sell	-36,483	Closed	-$874K	–	310
2023 Q2	$874K	Buy	+36,483	New	+$811K	0.46%	70
2022 Q3	–	Sell	-324	Closed	-$4K	–	370
2022 Q2	$4K	Sell	324 -1,260	-80%	-$23.5K	0.01%	357
2022 Q1	$38K	Sell	1,584 -1,682	-52%	-$40.7K	0.03%	392
2021 Q4	$76K	Buy	+3,266	New	+$65.7K	0.11%	246
2021 Q3	–	Sell	-252	Closed	-$6K	–	441
2021 Q2	$6K	Sell	252 -6,006	-96%	-$136K	0.01%	404
2021 Q1	$161K	Buy	6,258 +1,979	+46%	+$87.1K	0.18%	189
2020 Q4	$229K	Buy	4,279 +1,086	+34%	+$53.9K	0.26%	141
2020 Q3	$131K	Buy	+3,193	New	+$138K	0.13%	248
2020 Q2	–	Sell	-6,661	Closed	-$281K	–	442
2020 Q1	$281K	Buy	+6,661	New	+$274K	0.46%	66
2019 Q3	–	Sell	-16,832	Closed	-$450K	–	274
2019 Q2	$450K	Buy	16,832 +14,391	+590%	+$368K	0.25%	168
2019 Q1	$65K	Buy	+2,441	New	+$57K	0.04%	244